Ramsay Health (ASX:RHC) share price presents a reopening play: Fund manager

Could Ramsay Health make for a reopening investment? This fundie believes so…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has been an underperformer over the past year. During the last 12 months, shares in the healthcare facility operator have traded sideways, gaining ~2%. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has dished out a 23.7% return to investors over the same period.

Although, one fund manager is betting on the tide turning as COVID-19 restrictions ease across its operating geographies.

Let's take a look at why Sydney-based Perennial Partners are bullish on the Ramsay Health share price.

A woman opens and reaches into a big cardboard box, with a big smile on her face.

Image source: Getty Images

A big backlog filtering through

Firstly, the Perennial Value Australian Shares Trust invests in a broad swathe of ASX shares, with the aim of outperforming the S&P/ASX 300 Accumulation Index on a rolling 3-year basis. At the end of August, the trust held $761 million in funds under management.

To outperform the index, the fund must attempt to balance its investment weightings better than the index itself. As such, compared to the index, the Perennial Value fund is underweight on Rio Tinto Limited (ASX: RIO), Transurban Group (ASX: TCL), Goodman Group (ASX: GMG), Australia and New Zealand Banking Group Ltd (ASX: ANZ), and Afterpay Ltd (ASX: APT).

On the contrary, there are several ASX-listed companies in which the fund sees greater upside potential. One of these shares is Ramsay Health Care. As a result, the Perennial Value fund is overweight with Ramsay when comparing to its benchmark index.

In the near term, elective surgery restrictions in Australia are impacting the healthcare company's earnings. However, looking beyond this, the fund points out a likely bounce back in surgical volumes once restrictions lift.

Providing justification, Perennial drew attention to the increase in volumes in Ramsay's United Kingdom operations. Considering the UK is largely open again, procedures deferred by COVID-19 are now being tended to.

According to the Australian Institute of Health and Welfare, the median waiting time for elective surgery in Australia for 2019-2020 increased to 77 days from 66 days. On a similar note, The Age recently reported a significant blowout in Victoria's hospital waiting lists.

Specifically, the state's elective surgery waiting list has reached more than 65,000 people – with more than 30,000 procedures being cancelled last year.

Positioning for upside in Ramsay Health share price

The Perennial fund is putting its (investors') money where its mouth is. According to the trust's activity in August, the fund took profits in some of its outperforming holdings and redirected that capital elsewhere.

In gearing up for a reopening boom, Perennial allocated those proceeds to several ASX shares, including Ramsay Health.

The Ramsay Health share price finished the Monday trading session at $69.28.

Motley Fool contributor Mitchell Lawler owns shares of AFTERPAY T FPO and Ramsay Health Care Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Australian Clinical Labs delivers profit growth and stronger margins in FY26

Australian Clinical Labs’ FY26 earnings reveal profit growth and margin improvements despite market headwinds.

Read more »

medical research laboratory assistant examines solutions in test tubes
Healthcare Shares

CSL shares are rallying. Could tomorrow's results pour fuel on the fire?

One strong month isn't enough. CSL needs earnings recovery to follow.

Read more »

A man with a perplexed expression on his face scratches his head.
Healthcare Shares

4DMedical shares are up 670% — but why have they halved?

Can the company turn its commercial momentum into another explosive share-price rebound?

Read more »

Businesswoman with a pleased smile reading on her laptop at a desk in the office with a look of satisfaction.
Healthcare Shares

Are CSL shares dirt cheap and a strong buy?

There is plenty for CSL to prove next week. The current valuation is why I am still interested.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »